Talk Will Cover the Use of Pharsight Software for In-Vitro / In-Vivo
Correlation Modeling in Drug Development
MOUNTAIN VIEW, Calif., June 23 /PRNewswire-FirstCall/ -- Pharsight(R) Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Jason Chittenden, MS, Director of Training and Pre-Sales, will speak to members of the pharmaceutical and biotechnology industries attending the Dissolution Testing, Bioequivalence & Bioavailability Strategies Conference, to be held in London, United Kingdom, by Visiongain, at The Grosvenor -- Victoria Hotel, June 26th and 27th, 2008.
Mr. Chittenden will give a lecture on the use of Pharsight's software for in-vitro/in-vivo correlation (IVIVC) and its benefits in formulation design, bioequivalence, and development of dissolution specifications. Understanding and controlling the relationship between in-vitro release and in-vivo response in a compound plays a critical role in the development of modified-release formulations, generics, fixed-dose combination products, and drug delivery systems. The earlier in the drug development process IVIVC is implemented, the easier and more cost effective it is to implement all future changes in formulations.
"Doing dissolution analyses with IVIVC is a fast and inexpensive method
for obtaining optimal formulations as opposed to slow, expensive
bioavailability or bioequivalence (BA/BE) studies that provide hit or miss
results," said Shawn O'Connor, president, CEO, and chairman of Pharsight.
"Pharsight's IVIVC Toolkit(TM) for WinNonlin(R) guides researchers to
perform the right BA/BE studies and eliminate many that are unn
|SOURCE Pharsight Corporation|
Copyright©2008 PR Newswire.
All rights reserved